NCT03453112已完成3 期
A 12-week, Multicenter, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster 100/6mg NEXThaler, 2 Inhalations b.i.d, Versus Foster 100/6mg pMDI, 2 Puffs b.i.d in Patients With Controlled Asthma.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 494
- 试验地点
- 51
- 主要终点
- Change From Baseline to End of Treatment Period in Average Pre-dose Morning Peak Expiratory Flow (PEF)
研究概览
简要总结
Primary Objective
To demonstrate the non-inferiority of Foster® NEXThaler® 100/6 µg versus (vs.) Foster® pressurised metered dose inhaler (pMDI) 100/6 µg in terms of pulmonary function (change from baseline to the entire treatment period in average pre-dose morning peak expiratory flow [PEF]) in asthmatic patients.
Secondary Objectives
To evaluate the effect of the test treatments in terms of additional lung function parameters and clinical outcome measures, and to assess the safety and tolerability.
详细描述
This was a phase III, multinational, multicentre, randomised, double-blind, double-dummy, active-control, 2-arm parallel group study designed to evaluate the non-inferiority of Foster® NEXThaler® 100/6 µg (400/24 µg/day) versus Foster® pMDI 100/6 µg (400/24 µg/day) in patients with controlled asthma.
The study included the following phases:
- Pre-Screening Phase (Visit 0): Conducted within a maximum of 7 days before the screening visit (Visit 1), this phase provided patients with study details, obtained informed consent, and outlined medication restrictions.
- Screening and Run-in Phase (Visit 1, Week -4 to Visit 2, Week -2): Patients underwent eligibility assessments and transitioned into a 4-week open-label run-in period with Foster® pMDI 100/6 µg (400/24 µg/day) to establish baseline parameters.
- Randomisation Phase (Visit 3, Week 0): Eligible patients were randomised in a 1:1 ratio to receive either Foster® NEXThaler® 100/6 µg 2 inhalations bid (for a total daily dose of 400/24 µg/day) or Foster® pMDI 100/6 µg, 2 puffs bid (for a total daily dose of 400/24 µg/day) for 12 weeks. The allocation was managed via an Interactive Web Response System (IWRS) to ensure balanced treatment groups.
- Investigational Phase (Treatment Period: Weeks 0-12): Patients attended scheduled visits at Weeks 2, 4, 6, 8, 10, and 12 to monitor efficacy and safety.
Daily, patients recorded pre-dose morning and evening Peak Expiratory Flow (PEF), rescue medication use, and asthma symptoms using an electronic peak flow meter and e-diary. At each visit, lung function (FEV1, FVC, and PEF), asthma symptom scores, and rescue medication use were assessed. Vital signs (heart rate, blood pressure) and safety outcomes (adverse events, serious adverse events, and laboratory assessments) were monitored.
- Follow-Up Phase: A safety follow-up phone call was conducted 7-10 days after the final visit (Week 12) or early termination to assess any unresolved adverse events (AEs) or new concomitant medications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female outpatients, Chinese ethnicity aged ≥18 years, who signed an ICF prior to initiation of any study-related procedure;
- •Clinical diagnosis of asthma for a minimum of 6 months prior to V1 (Week -4) confirmed by a chest physician according to international guidelines updated 2018 (GINA) [1]. The evidence of asthma had to be confirmed through a documented positive response (in the last 24 months) either to a bronchial provocation test/challenge test or a reversibility test. In case the patient did not have any documented reversibility test or provocation/challenge test, a salbutamol reversibility test was performed at V1 (Week -4) within 10 to 30 minutes after administration of 400 µg of salbutamol pMDI [17]. Test response was positive if ΔFEV1 ≥12% and ≥200 mL over baseline.
- •Note: In case the reversibility threshold was not met at V1 (Week -4), the test could have been repeated once before V2 or at V2 (Week -2);
- •FEV1 >80% of the predicted normal value after appropriate washout from bronchodilators (checked at V1 [Week -4] and at the randomisation visit [V3, Week 0]);
- •Note: If this criterion was not met:
- •At V1 (Week -4), the test could have been repeated once before V2 or at V2 (Week -2);
- •At randomisation visit (V3, Week 0), the test could have been repeated once within 2 days after this visit;
- •ACQ-6 score <0.75 (checked at V1 [Week -4] and at the randomisation visit [V3, Week 0]);
- •Patients on previous regular treatment at a stable dose for at least 1 month prior to the screening visit (V1, Week -4) with either medium daily dose of ICS monotherapy (e.g. BDP-chlorofluorocarbons [CFC] >500-1000 µg/day or equivalent dose) or high daily dose of ICS monotherapy (e.g. BDP-CFC >1000 µg/day or equivalent dose) or low daily dose of ICS (e.g. BDP-CFC ≥200-500 µg/day or equivalent dose)/LABA free/fixed combination or medium daily dose of ICS (e.g. BDP-CFC >500-1000 µg/day or equivalent dose)/LABA free/fixed combination;
- •A cooperative attitude and ability to be trained to the proper use of DPI and pMDI inhalers and an electronic peak flow meter (checked at the screening visit [V1, Week -4] and at the randomisation visit [V3, Week 0]);
- •At least seven valid pre-dose morning PEF measurements in the last 14 days of the run-in period were necessary (checked at the randomisation visit [V3, Week 0]).
排除标准
- •Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) unless they were using one or more of the following highly effective contraceptive measures:
- •Placement of an intrauterine device or intrauterine hormone-releasing system;
- •Combined (oestrogen and progesterone containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal);
- •Progesterone-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable);
- •Bilateral tubal occlusion;
- •Vasectomised partner;
- •Sexual abstinence; Reliable contraception had to be maintained throughout the study. Any postmenopausal women (physiologic menopause defined as "12 consecutive months of amenorrhoea without an alternative medical cause") or women permanently sterilised (e.g. bilateral oophorectomy, hysterectomy or bilateral salpingectomy) could be enrolled in the study.
- •Pregnancy testing was carried out during the course of the study in all women of childbearing potential: serum pregnancy test was performed at screening (V1, Week -4) and end of treatment (V9, Week 12), urine pregnancy test was performed at all visits except V0 (Week -5) and V9 (Week 12);
- •Intermittent asthma or asthma occurring only during episodic exposure to an allergen or a chemical sensitiser;
- •History of near fatal asthma (e.g. brittle asthma, hospitalisation for asthma exacerbation in an intensive care unit);
- •Diagnosis of chronic obstructive pulmonary disease as defined by the current global initiative for chronic obstructive lung disease (GOLD) guidelines updated 2016 [18];
- •Current smokers or ex-smokers with total cumulative exposure equal or more than 10 pack-years or having stopped smoking 1 year or less prior to screening (V1, Week -4);
- •Severe asthma exacerbation leading to intake of systemic corticosteroids (≥10 days) within 1 month prior to inclusion or moderate/severe asthma exacerbation (according to international guidelines updated 2018 [GINA] [1]) during the run-in period (checked at the screening visit [V1, Week -4] and at the randomisation visit [V3, Week 0]);
- •Lower respiratory tract infections (e.g. pneumonia) affecting the patient's asthma within 1 month prior to inclusion;
- •History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency, or any other significant lung disease;
- •Diagnosis of restrictive lung disease;
- •Patients treated with oral or parenteral corticosteroids in the previous 2 months before V1 (Week -4; 3 months for parenteral depot corticosteroids);
- •Intolerance or contra-indication to treatment with β2-agonists and/or ICS or allergy to any component of the study treatments;
- •Having received an investigational medication within 2 months before screening (V1, Week -4);
- •Patients who had a clinical or functional uncontrolled respiratory, haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease, or any condition (e.g. major surgery) that might have, in the judgment of the Investigator, represented for the patients an undue risk or that could have compromised the results or interpretation of the study;
- •History or current evidence of uncontrolled heart failure, clinically relevant coronary artery disease, recent myocardial infarction, severe hypertension, uncontrolled cardiac arrhythmias;
- •Clinically relevant laboratory abnormalities such as (but not limited to) hypokalaemia (<3.5 mEq/L), that might have compromised patient's safety or compliance, interfered with evaluation, or precluded completion of the study, in the judgment of the Investigator. Patients with uncontrolled diabetes including patients with a history of fasting plasma glucose levels consistently out of the normal range (>140 mg/dL) or HbA1C >8%;
- •Patients who had an abnormal 12-lead ECG (i.e. QRS interval [QRS] >120 ms and/or PR interval [PR] >210 ms and/or HR <45 beats per minute [bpm] and/or HR >110 bpm and/or Fridericia-corrected QT interval [QTcF] >450 ms for males or QTcF >470 ms for females) or 12-lead ECG evaluated as abnormal clinically significant (CS) by the Investigator, at screening (V1, Week -4);
- •Patients who had a concomitant disease of poor prognosis (e.g. cancer);
- •Patients treated with monoclonal antibodies (e.g. anti-immunoglobulin E [anti-IgE] antibodies);
- •Patients treated with non-potassium sparing diuretics (unless administered at a fixed dose combination with a potassium conserving medication), non-selective β1-blocking medications, quinidine, quinidine-like antiarrhythmics or any medication with a corrected QT interval (QTc) prolongation potential, or a history of QTc prolongation;
- •Patients treated with monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants, unless already taken at stable doses in the month before screening (V1, Week -4) and without any safety concern;
- •Patients who were receiving therapy that could interact with steroids, such as enzyme inhibitors (macrolides, antifungal therapy [not topical]) or inducers (anticonvulsants, rifampicin);
- •Inability to comply with study procedures or with study treatment intake.
研究组 & 干预措施
Foster 100/6µg NEXThaler
Experimental
Patients in this arm received Foster® NEXThaler® 100/6 µg, a fixed-dose combination of beclometasone dipropionate (BDP) 100 µg and formoterol fumarate (FF) 6 µg per actuation, delivered via a breath-actuated dry powder inhaler (DPI).
Treatment Details:
- Dosage: 2 inhalations twice daily (b.i.d.), totaling 400/24 µg BDP/FF daily.
- Duration: 12 weeks.
- Administration: First dose under medical supervision at randomization (Week 0).
Blinding & Control Treatment:
- A double-dummy design was used. Patients also received a placebo pMDI (matching active pMDI), administered as 2 puffs b.i.d. to maintain blinding.
Background Therapy:
- Salbutamol was provided as rescue medication.
Patient Training & Compliance:
- Inhaler use was assessed at visits, with retraining as needed; patients used an AeroChamber Plus™ spacer if necessary, and each inhaler was labeled with "sun" (morning) and "moon" (evening) stickers.
干预措施: Foster 100/6µg NEXThaler (Drug)
Foster 100/6µg pMDI
Active Comparator
Patients in this arm received Foster® pMDI 100/6 µg, a fixed-dose combination of beclometasone dipropionate (BDP) 100 µg and formoterol fumarate (FF) 6 µg per actuation, delivered via a pressurized metered-dose inhaler (pMDI).
Treatment Details:
- Dosage: 2 puffs twice daily (b.i.d.), totaling 400/24 µg BDP/FF daily.
- Duration: 12 weeks.
- Administration: First dose under medical supervision at randomization (Week 0).
Blinding & Control Treatment:
- A double-dummy design was used. Patients also received a placebo DPI (matching active DPI), administered as 2 inhalations b.i.d. to maintain blinding.
Background Therapy:
- Salbutamol was provided as rescue medication.
Patient Training & Compliance:
- Inhaler use was assessed at visits, with retraining as needed; patients used an AeroChamber Plus™ spacer if necessary, and each inhaler was labeled with "sun" (morning) and "moon" (evening) stickers.
干预措施: Foster 100/6µg pMDI (Drug)
结局指标
主要结局
Change From Baseline to End of Treatment Period in Average Pre-dose Morning Peak Expiratory Flow (PEF)
时间窗: Baseline (Week 0, Visit 3) and Week 12 (EoT)
PEF= peak expiratory flow. The peak expiratory flow (also known as a peak flow or peak flow rate) is the maximal rate that a person can exhale during a short maximal expiratory effort after a full inspiration. In this study PEF (L/min) was monitored twice daily using a portable electronic peak flow meter before medication intake: morning (7:00-9:00 am) and evening (7:00-9:00 pm). Each session required at least two blows, with the highest valid value recorded. * Baseline pre-dose morning PEF was calculated as the mean of all valid pre-dose morning Best PEF values from the last 14 days before randomization (Week 0, Visit 3). * The average pre-dose morning PEF over the entire treatment period was computed as: ∑Valid pre-dose morning Best PEF values (treatment period) / Number of days with available data * Valid pre-dose morning Best PEF values = Highest value recorded from at least two PEF measurements per session, within the range 50-900 L/min
次要结局
- Change From Baseline to Each 2-week (Inter-visit) Treatment Period in Average Pre-dose Morning Peek Expiratory Flow (PEF)(Baseline (Visit 3, Week 0, Randomization), Week 2 (Visit 4), Week 4 (Visit 5), Week 6 (Visit 6), Week 8 (Visit 7), Week 10 (Visit 8), Week 12 (Visit 9, End of Treatment - EOT))
- Change From Baseline to Each 2-week (Inter-visit) Treatment Period and to the Entire Treatment Period in Average Pre-dose Evening PEF(Baseline (Visit 3, Week 0, Randomization), Week 2 (Visit 4), Week 4 (Visit 5), Week 6 (Visit 6), Week 8 (Visit 7), Week 10 (Visit 8), Week 12 (Visit 9, End of Treatment - EOT) and across the 12 weeks.)
- Change From Baseline to Each 2-week (Inter-visit) Treatment Period and to the Entire Treatment Period in Daily PEF Variability(Baseline (Visit 3, Week 0, Randomization), Week 2 (Visit 4), Week 4 (Visit 5), Week 6 (Visit 6), Week 8 (Visit 7), Week 10 (Visit 8), Week 12 (Visit 9, End of Treatment - EOT) and across the 12 weeks)
- Change From Baseline to Each 2-week (Inter-visit) Treatment Period and to the Entire Treatment Period in Average Use of Rescue Medication (Number of Puffs/Day)(Baseline (Visit 3, Week 0, Randomization), Week 2 (Visit 4), Week 4 (Visit 5), Week 6 (Visit 6), Week 8 (Visit 7), Week 10 (Visit 8), Week 12 (Visit 9, End of Treatment - EOT) and across the 12 weeks)
- Change From Baseline to Each 2-week (Inter-visit) Treatment Period and to the Entire Treatment Period in Percentage of Rescue Medication-Free Days(Baseline (Visit 3, Week 0, Randomization), Week 2 (Visit 4), Week 4 (Visit 5), Week 6 (Visit 6), Week 8 (Visit 7), Week 10 (Visit 8), Week 12 (Visit 9, End of Treatment - EOT) and across the 12 weeks)
- Change From Baseline to Each 2-week (Inter-visit) Treatment Period and to the Entire Treatment Period in Average Total Morning Asthma Symptom Score(Baseline (Visit 3, Week 0, Randomization), Week 2 (Visit 4), Week 4 (Visit 5), Week 6 (Visit 6), Week 8 (Visit 7), Week 10 (Visit 8), Week 12 (Visit 9, End of Treatment - EOT) and across the 12 weeks)
- Change From Baseline to Last Visit in ACQ-6 Score(Week 12 (Visit 9, End of Treatment - EOT))
- Change From Baseline to Each 2-week (Inter-visit) Treatment Period and to the Entire Treatment Period in Average Total Evening Asthma Symptom Scores(Baseline (Visit 3, Week 0, Randomization), Week 2 (Visit 4), Week 4 (Visit 5), Week 6 (Visit 6), Week 8 (Visit 7), Week 10 (Visit 8), Week 12 (Visit 9, End of Treatment - EOT) and across the 12 weeks)
- Change From Baseline to Each 2-week (Inter-visit) Treatment Period and to the Entire Treatment Period in Percentage of Asthma Symptom-Free Days(Baseline (Visit 3, Week 0, Randomization), Week 2 (Visit 4), Week 4 (Visit 5), Week 6 (Visit 6), Week 8 (Visit 7), Week 10 (Visit 8), Week 12 (Visit 9, End of Treatment - EOT) and across the 12 weeks)
- Change From Baseline to Each 2-week (Inter-visit) Treatment Period and to the Entire Treatment Period in Percentage of Asthma Control Days(Baseline (Visit 3, Week 0, Randomization), Week 2 (Visit 4), Week 4 (Visit 5), Week 6 (Visit 6), Week 8 (Visit 7), Week 10 (Visit 8), Week 12 (Visit 9, End of Treatment - EOT) and across the 12 weeks)
- Change From Baseline in Pre-Dose Morning FEV1 at Each Clinic Visit(Baseline (Visit 3, Week 0, Randomization), Week 2 (Visit 4), Week 4 (Visit 5), Week 6 (Visit 6), Week 8 (Visit 7), Week 10 (Visit 8), Week 12 (Visit 9, End of Treatment - EOT))
- Change From Baseline in Pre-Dose Morning FVC at Each Clinic Visit(Baseline (Visit 3, Week 0, Randomization), Week 2 (Visit 4), Week 4 (Visit 5), Week 6 (Visit 6), Week 8 (Visit 7), Week 10 (Visit 8), Week 12 (Visit 9, End of Treatment - EOT))
- Number of Participants With at Least One Adverse Event (TEAE) or Adverse Drug Reaction (ADR)(From Week 0 (Visit 3, Randomization) to Week 12 (Visit 9, EoT))
研究者
研究点 (51)
Loading locations...
相似试验
进行中（未招募）
3 期
A clinical trial, involving several sites in several countries, with a duration of 12 weeks, where patients, medical doctors and the sponsor do not know the treatment taken by the patient (between one study treatment and another one) with the scope of evaluating the safety of study treatment in comparison with another similar one in subjects with asthma.RespiratoryAsthmaISRCTN17142179Chiesi (Italy)513
招募中
1 期
A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 pMDI 200/6/12.5 µg HFA-152a, compared to CHF5993 pMDI 200/6/12.5 µg HFA-134a, in subjects with asthmaModerate to severe controlled asthma according to Step 4 and Step 5 of the Global Initiative for Asthma (GINA) 2022 Guidelines.MedDRA version: 20.0Level: PTClassification code: 10003553Term: Asthma Class: 100000004855CTIS2023-503333-22-00Chiesi Farmaceutici S.p.A.777
进行中（未招募）
1 期
A 12-week multicentre, randomised, double-blind, parallel group, Phase IIpilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mgbid (400 mg/d), cizolirtine citrate 300 mg bid (600 mg/d) and cizolirtinecitrate 400 mg bid (800 mg/d) versus placebo in the treatment of patientswith Stress Urinary Incontinence (SUI)Stress Urinary IncontinenceEUCTR2005-000107-33-ESaboratorios Dr. Esteve, S.A.180
进行中（未招募）
不适用
A 12-week multicentre, randomised, double-blind, parallel group, Phase IIpilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mgbid (400 mg/d), cizolirtine citrate 300 mg bid (600 mg/d) and cizolirtinecitrate 400 mg bid (800 mg/d) versus placebo in the treatment of patientswith Stress Urinary Incontinence (SUI)Stress Urinary IncontinenceEUCTR2005-000107-33-SEaboratorios Dr. Esteve, S.A.180
进行中（未招募）
1 期
A 12-week multicentre, randomised, double-blind, parallel group, Phase IIpilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mgbid (400 mg/d), cizolirtine citrate 300 mg bid (600 mg/d) and cizolirtinecitrate 400 mg bid (800 mg/d) versus placebo in the treatment of patientswith Stress Urinary Incontinence (SUI)Stress Urinary IncontinenceEUCTR2005-000107-33-CZaboratorios Dr. Esteve, S.A.180